(image: Cellebrite DI Ltd)
PETAH TIKVA, Israel and TYSONS CORNER, Va., June 30 (Korea Bizwire) — Cellebrite DI Ltd. (Nasdaq: CLBT), a global leader in Digital Intelligence (DI) solutions for the public and private sectors, today announced the general availability of the Cellebrite Physical Analyzer Ultra Series (PA Ultra Series), the next generation of PA and the de-facto industry standard for digital data examination.
PA Ultra Series is a revolutionary solution that further empowers investigators to uncover key pieces of case-relevant digital evidence and examine digital data more efficiently, to help secure more convictions, accelerate justice, and close cases faster. PA Ultra Series will significantly boost Cellebrite’s Collection & Review offerings as part of the Digital Intelligence suite of solutions.
PA Ultra Series will enable investigation teams to leverage an upgraded solution that can process a higher volume of computer, cloud, and mobile data, allow cases to be opened without the need to reparse data and support multiple cases and evidence per device with enhanced location data from a new customizable dashboard. PA Ultra will also enable data enrichment for cryptocurrency, ranging from leading blockchain data platforms to tracking transactions.
Ronnen Armon, Chief Products & Technologies Officer, said: “PA Ultra Series transforms PA’s data processing, decoding, and reporting capabilities. We are confident that our continued innovation will empower examiners and law enforcement agencies to make more efficient and insightful investigative decisions that will lead to uncovering the truth and securing more convictions.”
Additionally, after successful beta testing and showcasing the pre-release, the SaaS version of Cellebrite Premium, an industry-leading advanced access solution, is now available for customers. With the general release of PA Ultra Series and the general availability of a SaaS-based version of Cellebrite Premium, Cellebrite has built upon its position as the global leader in the Digital Intelligence market. The Company provides a complete Collection & Review technology stack to its public and private sector customers, dramatically boosting our customer’s ability to analyze data in investigations and manage this process in the cloud.
For more information on Cellebrite PA Ultra Series, please visit https://cellebrite.com/en/pa-ultra.
For more information on Cellebrite Premium-as-a-Service, please visit: https://cellebrite.com/en/premium-as-a-service/.
About Cellebrite
Cellebrite’s (Nasdaq: CLBT) mission is to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the world. We are a global leader in Digital Intelligence solutions for the public and private sectors, empowering organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. Trusted by thousands of leading agencies and companies worldwide, Cellebrite’s Digital Intelligence platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. To learn more visit us at www.cellebrite.com, https://investors.cellebrite.com, or follow us on Twitter at @Cellebrite.
Caution Regarding Forward Looking Statements
This document includes “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “will,” “appear,” “approximate,” “foresee,” “might,” “possible,” “potential,” “believe,” “could,” “predict,” “should,” “could,” “continue,” “expect,” “estimate,” “may,” “plan,” “outlook,” “future” and “project” and other similar expressions that predict, project or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include estimated financial information. Such forward-looking statements with respect to revenues, earnings, performance, strategies, prospects, and other aspects of Cellebrite’s business are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to: Cellebrite’s ability to keep pace with technological advances and evolving industry standards; Cellebrite’s material dependence on the acceptance of its solutions by law enforcement and government agencies; real or perceived errors, failures, defects or bugs in Cellebrite’s DI solutions; Cellebrite’s failure to maintain the productivity of sales and marketing personnel, including relating to hiring, integrating and retaining personnel; uncertainties regarding the impact of macroeconomic and/or global conditions, including COVID-19 and military actions involving Russia and Ukraine; intense competition in all of Cellebrite’s markets; the inadvertent or deliberate misuse of Cellebrite’s solutions; political and reputational factors related to Cellebrite’s business or operations; risks relating to estimates of market opportunity and forecasts of market growth; Cellebrite’s ability to properly manage its growth; risks associated with Cellebrite’s credit facilities and liquidity; Cellebrite’s reliance on third-party suppliers for certain components, products, or services; challenges associated with large transactions and long sales cycle; risks that Cellebrite’s customers may fail to honor contractual or payment obligations; risks associated with a significant amount of Cellebrite’s business coming from government customers around the world; risks related to Cellebrite’s intellectual property; security vulnerabilities or defects, including cyber-attacks, information technology system breaches, failures or disruptions; the mishandling or perceived mishandling of sensitive or confidential information; the complex and changing regulatory environments relating to Cellebrite’s operations and solutions; the regulatory constraints to which we are subject; risks associated with different corporate governance requirements applicable to Israeli companies and risks associated with being a foreign private issuer and an emerging growth company; market volatility in the price of Cellebrite’s shares; changing tax laws and regulations; risks associated with joint, ventures, partnerships and strategic initiatives; risks associated with Cellebrite’s significant international operations; risks associated with Cellebrite’s failure to comply with anti-corruption, trade compliance, anti-money-laundering and economic sanctions laws and regulations; risks relating to the adequacy of Cellebrite’s existing systems, processes, policies, procedures, internal controls and personnel for Cellebrite’s current and future operations and reporting needs; and other factors, risks and uncertainties set forth in the section titled “Risk Factors” in Cellebrite’s annual report on form 20-F filed with the SEC on March 29, 2022 and in other documents filed by Cellebrite with the U.S. Securities and Exchange Commission (“SEC”), which are available free of charge at www.sec.gov. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, in this communication or elsewhere. Cellebrite undertakes no obligation to update its forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.
Cellebrite Contacts
Media
Victor Cooper
Public Relations and Corporate Communications Director
Victor.cooper@cellebrite.com
+1 404.804.5910
Investors
Anat Earon-Heilborn
VP Investor Relations
+972 73 394 8440
investors@cellebrite.com
Source: Cellebrite DI Ltd via GLOBE NEWSWIRE
